The Omeros Building
201 Elliott Avenue West
Seattle, WA 98119
United States
206 676 5000
https://www.omeros.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 196
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Gregory A. Demopulos M.D. | Co-Founder, Chairman, CEO & President | 1.79M | N/A | 1959 |
Mr. Michael A. Jacobsen | Chief Accounting Officer, VP of Finance & Treasurer | 518.6k | N/A | 1958 |
Mr. Peter B. Cancelmo J.D. | VP, General Counsel & Corporate Secretary | 503.24k | N/A | 1979 |
Dr. Pamela Pierce Palmer M.D., Ph.D. | Co-Founder | N/A | N/A | 1963 |
Dr. George A. Gaitanaris M.D., Ph.D. | Chief Scientific Officer & VP of Science | N/A | N/A | 1957 |
Mr. Peter W. Williams | Vice President of Human Resources | N/A | N/A | 1968 |
Dr. Catherine A. Melfi Ph.D. | Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems | N/A | N/A | 1959 |
Ms. Nadia Dac | VP & Chief Commercial Officer | N/A | N/A | 1970 |
Dr. Andreas Grauer M.D. | Chief Medical Officer | N/A | N/A | 1961 |
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that has completed pivotal studies for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA); that is in Phase III clinical trial for immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that is in phase Ib clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders; and OMS405 that is in phase II clinical trials for opioid and nicotine addiction. In addition, the company develops MASP-2-small-molecule inhibitors for the treatment of aHUS, HSCT-TMA, and age-related macular degeneration; GPR174 inhibitors and chimeric antigen receptor T-Cell and adoptive T-Cell therapies for various cancers; and G protein-coupled receptors for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular, musculoskeletal, and other disorders. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
Omeros Corporation’s ISS Governance QualityScore as of March 1, 2024 is 7. The pillar scores are Audit: 8; Board: 9; Shareholder Rights: 5; Compensation: 8.